1. Home
  2. BDTX vs INTT Comparison

BDTX vs INTT Comparison

Compare BDTX & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.88

Market Cap

171.9M

Sector

Health Care

ML Signal

N/A

Logo inTest Corporation

INTT

inTest Corporation

N/A

Current Price

$11.90

Market Cap

148.4M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BDTX
INTT
Founded
2014
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
171.9M
148.4M
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
BDTX
INTT
Price
$1.88
$11.90
Analyst Decision
Buy
Strong Buy
Analyst Count
8
3
Target Price
$10.00
★ $19.67
AVG Volume (30 Days)
★ 475.9K
90.0K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 130.71
N/A
EPS
N/A
★ 0.06
Revenue
N/A
★ $66,801,000.00
Revenue This Year
N/A
$21.53
Revenue Next Year
N/A
$7.05
P/E Ratio
★ N/A
$193.83
Revenue Growth
N/A
★ 66.06
52 Week Low
$1.60
$7.07
52 Week High
$4.94
$20.00

Technical Indicators

Market Signals
Indicator
BDTX
INTT
Relative Strength Index (RSI) 40.78 52.90
Support Level $1.76 $11.17
Resistance Level $1.90 $11.83
Average True Range (ATR) 0.08 0.47
MACD -0.01 0.18
Stochastic Oscillator 26.09 88.82

Price Performance

Historical Comparison
BDTX
INTT

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

Share on Social Networks: